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AbstrAct
Objective To map out the current provision of 
interventional oncology (IO) services in the UK.
Design Cross-sectional multicentre study.
setting All National Health Service (NHS) trusts in England 
and Scottish, Welsh and Northern Ireland health boards.
Participants Interventional radiology (IR) departments in 
all NHS trusts/health boards in the UK.
results A total of 179 NHS trusts/health boards were 
contacted. We received a 100% response rate. Only 
19 (11%) institutions had an IO lead. 144 trusts (80%) 
provided IO services or had a formal pathway of referral in 
place for patients to a recipient trust. 21 trusts (12%) had 
plans to provide an IO service or formal referral pathway 
in the next 12 months only. 14 trusts (8%) did not have 
a pathway of referral and no plans to implement one. 70 
trusts (39%) offered supportive and disease-modifying 
procedures. One trust had a formal referral pathway for 
supportive procedures. 73 trusts (41%) provided only 
supportive procedures (diagnostic or therapeutic). Of these, 
43 (59%) had a referral pathway for disease-modifying 
IO procedures, either from a regional cancer network or 
through IR networks and 30 trusts (41%) did not have a 
referral pathway for disease-modifying procedures.
conclusion The provision of IO services in the UK is 
promising; however, collaborative networks are necessary 
to ensure disease-modifying IO procedures are made 
accessible to all patients and to facilitate larger registry 
data for research with commissioning of new services.
IntrODuctIOn
More than one in three people will develop 
cancer in their lifetime.1 Since the National 
Health Service (NHS) Cancer Plan in 2000, 
the Department of Health has strived to 
improve diagnosis and treatment.1 As part of 
the NHS Cancer Plan to deliver world-class 
cancer services, there is a drive to achieve 
better outcomes by ensuring all patients have 
access to the best treatments available.2 Wide 
variation remains in performance across the 
country with major differences in access to 
cancer services.1
Interventional oncology (IO) the use of 
image-guided techniques to diagnose and treat 
patients with cancer is fast becoming the fourth 
pillar of oncological care alongside medical, 
surgical and radiation oncology; the Royal 
College of Radiologists have set out best prac-
tice guidance for the incorporation of IO into 
all cancer services nationally.3
Supportive and symptomatic procedures 
were defined as those providing relief from 
tumour-related symptoms, but not modifying 
the underlying malignant disease process 
and include diagnostic tests such as image-
guided biopsy which ‘support’ the provi-
sion of definitive treatment.3 These may be 
palliative procedures such as image-guided 
drainage or stent insertion. Disease-modi-
fying procedures were defined as those where 
the intent is to modify malignant progression 
and/or modify the prognosis and include 
image-guided ablation, transarterial chemo-
embolisation (TACE) and selective internal 
radiation therapy (SIRT).
There remains a significant shortage of 
interventional radiologists, who are the 
primary contributors towards IO, with almost 
half of services in England unable to provide 
a local or networked out of hours access to 
interventional radiology (IR).4 Undoubtedly, 
this shortfall will have consequences on the 
provision of elective IO services in the UK 
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Research
strengths and limitations of this study
 ► This is the first study to investigate the provision of 
interventional oncology services in the UK.
 ► The sample size is large and covers all acute trusts 
and health boards in the UK.
 ► Cross-sectional study design allowed for multiple 
variables to be studied.
 ► Data were self-reported and therefore at risk of 
incompleteness.
 ► Limitations include those inherent to survey/
questionnaire format, including subjective bias.
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Figure 1 UK map showing the overall provision of 
interventional oncology (IO) services throughout the UK.
and potentially affect patient care through limitations to 
access.
The current provision of IO services throughout the UK 
is unknown; therefore, NHS commissioners are unable 
to realistically factor IO into national cancer pathways as 
evident in a previous Department of Health publication,1 
which did not acknowledge IO as a treatment option for 
patients.
The primary objective of this cross-sectional study was 
to map out the current provision of IO services in the 
UK. We also sought to uncover formal patient referral 
pathways, the types of IO procedures offered and any 
limitations to providing IO. Ultimately, we aim to develop 
IO networks and improve access to these treatments for 
patients with cancer.
The survey was designed and undertaken by  theInter-
ventional Oncology United Kingdom (IOUK) group, a 
specialist interest group of the British Society of Interven-
tional Radiology(BSIR).
MethODs
No research ethics committee approval was required for 
this data-gathering project. No patient identifiable data 
was captured.
This cross-sectional study involved all acute NHS Foun-
dation Trusts in England5 and all health boards in Scot-
land, Wales and Northern Ireland which were contacted 
via email with the survey (see online supplementary mate-
rial). This was followed by a telephone follow-up of all 
hospital radiology departments that did not complete the 
survey within 2 weeks of the first email being sent out. 
Telephone follow-up was conducted by a single radiolo-
gist (JZ). The survey could be completed by any of the 
following: The head of department of radiology/IR, any 
consultant radiologist (diagnostic or interventional) or 
superintendent radiographer who has insight into the 
local provision of services.
The surveys key points were the following:
 ► Are IO procedures offered in the trust?
 ► If so, are these supportive treatments only or both 
supportive and disease modifying?
 ► We asked about the types of procedures undertaken.
 ► If no IO procedures are offered, is there an agreed 
formal pathway to another recipient trust?
 ► If there was no agreed pathway, was there a plan to 
provide IO or a pathway in the next 12 months?
 ► What barriers are there to setting up an IO service?
The full survey can be found in the online supplemen-
tary material.
Following the initial survey, we followed up all trusts/
health boards which only offered supportive treat-
ments to see if there were formal referral pathways for 
disease-modifying procedures.
A formal referral pathway was defined as an existing 
mechanism of referral through a multidisciplinary team 
responsible for the patient, usually through a pre-existing 
local oncology or radiology network.
results
A total of 179 NHS trusts or health boards were 
contacted throughout the UK. We received 100% 
response rate. The responses came from consultant 
interventional and diagnostic radiologists and superin-
tendent radiographers who had insight into the local 
provision of services.
One hudred and forty-three trusts (80%) had an IR 
department in their trust. All trusts with an IR depart-
ment offered IO procedures. Only 19 (11%) institutions 
had an IO lead.
One hundred and forty-four trusts (80%) provided IO 
services or had a formal pathway of referral in place for 
patients to a recipient trust (figures 1 and 2), of which 
137 trusts (77%) stated what types of IO services they 
offered. Twenty-one trusts (12%) had plans to provide 
an IO service or formal referral pathway in the next 12 
months only. Fourteen trusts (8%) did not have a pathway 
of referral and no plans to implement one.
Seventy trusts (39%) offered both supportive and 
disease-modifying procedures (figure 3). One trust had a 
formal referral pathway for supportive procedures. Seven-
ty-three trusts (41%) provided only supportive proce-
dures (diagnostic or therapeutic).
The number of trusts providing each supportive/symp-
tomatic IO procedure and disease-modifying procedure 
are shown in table 1 and table 2, respectively. The seven 
trusts that gave no details to which IO procedures were 
offered were excluded when calculating the percentages.
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Figure 2 Middle pie chart (A) displaying total number/
percentage of trusts which offer interventional oncology (IO) 
or have a referral pathway, number which plan to set up IO 
service or referral pathway in the next 12 months (all English 
trusts) and those without any plans to set up an IO service 
pathway. The top (B) and bottom (C) pie charts display the 
breakdown of healthcare trusts/health boards by country.
Figure 3 UK map showing what types of interventional 
oncology (IO) procedures (supportive and/or disease-
modifying procedures) are undertaken in each National 
Health Service trust/health board.
Out of 179 (72%), 129 trusts offered therapeutic IO 
procedures after excluding trusts, which only offered 
diagnostic image-guided biopsy. Figures 4 and 5 show the 
maps of the trusts providing each type of disease-modi-
fying procedure.
For England only, a total of 153 NHS Foundation 
trusts in England were contacted. One hundred and 
twenty-seven (83%) trusts provided IO services or had a 
formal pathway of referral to another agreed recipient 
trust for IO procedures (figure 1). Out of the 26 that did 
not have a formal referral pathway, 21 (14%) trusts had 
plans to provide an IO service or formal referral pathway 
for patients to have IO at another trust within the next 
12 months. Five (3%) trusts did not have a pathway and 
had no plans of providing IO or a referral pathway in the 
next 12 months (figure 1). Out of 127 (45%), 57 trusts 
providing IO offered both supportive and disease-mod-
ifying procedures (figure 3). Out of 127 (55%), 70 
provided only supportive procedures.
For Scotland, 10 out of 14 health boards provided IO 
or had a formal pathway of referral to a specialist hospital 
in another health board (Glasgow or Edinburgh). Of 
these, eight health boards provided both supportive and 
disease-modifying IO, while two provided only supportive 
IO. Four health boards (29%) did not provide IO and 
did not have plans to provide a pathway in the next 12 
months.
For Wales, six out of seven health boards (86%) 
provided IO or had a referral pathway in place. Four 
Welsh health boards (57%) provided both types of IO, 
one health board provided only supportive IO and one 
had a formal referral pathway. One Welsh health board 
did not offer IO or have a referral pathway implemented 
in the next 12 months.
Only one out of five health boards in Northern Ireland 
(Belfast Health and Social Care Trust) provided IO (both 
types). Four health boards did not have plans to offer IO 
or have a referral pathway implemented in the next 12 
months.
Out of the 70 English NHS trusts and three Scottish/
Welsh Health Boards, which provided only supportive 
IO, 43 trusts (59%) had a referral pathway to another 
hospital/trust for disease-modifying IO procedures. This 
was from a local regional cancer network referral initi-
ated following a formal discussion at the multidisciplinary 
team meeting or through IR networks. Thirty trusts 
(41%) did not have a referral pathway for disease-mod-
ifying procedures.
The most common barriers to providing disease-mod-
ifying IO were insufficient funding, lack of staff, lack of 
support from other non-radiology clinicians, having a 
pathway already in place and problems with recruitment 
into IR.
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Table 1 Type of supportive/symptomatic IO procedure 
and number of trusts that offer each and percentage of total 
number of trusts that provided information on the types of 
procedure offered (n=137) 
Type of supportive/symptomatic IO 
procedure
No of 
trusts
Percentage 
of total
Image-guided biopsy 137 100
Nephrostomy 129 94
Image-guided drainage 128 93
Central venous catheter 125 91
Ureteric stenting 124 91
Biliary drainage and stenting 118 86
Vena caval filtration 88 64
Gastrointestinal stenting 87 64
Percutaneous transhepatic 
cholangiography 84 61
Enteral tube placement, for example, 
radiologically inserted gastrostomy 81 59
Vena caval stenting 79 58
Ascitic diversion 39 28
Vertebroplasty 6 4
Isolated perfusion chemotherapy 5 4
Out of 144, 7 who offered IO did not include what procedures were 
offered and were excluded from calculations.
IO, interventional oncology.
Table 2 Type of disease-modifying IO procedures and no 
of trusts that offer each and percentage of total no of trusts 
(n=179)
Type of disease-modifying IO 
procedure
No of 
trusts Percentage
Transarterial chemoembolisation 40 22
Liver ablation 39 22
Kidney ablation 39 22
Lung ablation 28 16
Bone ablation 18 10
Selective internal radiation therapy 17 9
Prostate ablation 2 1
IO, interventional oncology.
Figure 4 UK map showing the provision of ablation 
services: (A) renal ablation, (B) liver ablation, (C) bone ablation 
and (D) lung ablation.
Figure 5 UK map showing the provision of (A) transarterial 
chemoembolisation and (B) selective internal radiation 
therapy.
DIscussIOn
Overall, the provision of IO in the UK is unevenly spread. 
Based on the Royal College of Radiologists definition 
of ‘supportive’ IO,1 this encompasses many routine 
procedures that can be carried out by diagnostic radiol-
ogists which is reflected in the excellent availability of 
these procedures throughout the UK. Beyond basic 
image-guided drainage procedures, the provision of 
specialist vascular, gastrointestinal or biliary ‘symptom-
atic’ intervention is less routinely available apart from 
in the larger tertiary centres which were also providing 
disease-modifying IO. This highlights important areas to 
target nationally for radiology and IO training.
Given the vital role of IR in the management of critically 
ill patients, the comprehensive provision of supportive IO 
in most parts of the UK reflects the drive to train more 
radiologists with basic interventional skills, which are also 
transferrable to IO.6 Only one trust without an IR depart-
ment offered IO. We were unable to capture if most of the 
IO procedures were done by the IR department or not, 
with institutions occasionally splitting non-vascular (eg, 
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ablation) and vascular interventions (eg, TACE) between 
the diagnostic radiologists and the interventional radiol-
ogists who also have to cover the on-call service for 
non-oncology-related emergency procedures such as 
trauma, bleeding or aortic syndromes. A major recruit-
ment drive currently is the provision of on-call IR services 
and given the overlap between IO and IR training, emer-
gency IR provision is therefore linked with the provision 
of IO services not only for maintaining the availability of 
supportive services in small district hospitals, but also for 
the provision of disease-modifying IO in specialist centres. 
Additional need for interventional radiographers and 
nursing cover for IO services should not be overlooked 
either to allow a new IO service to be introduced.
We acknowledge that disease-modifying treatments 
form a smaller proportion of IO workload and central-
isation of this is happening as part of the current NHS 
model for cancer services.7 One argument for this model 
in the context of IO is to ensure that more complex IO 
procedures are undertaken by those who carry out a suffi-
cient number of cases to maintain competency; however, 
this should not preclude suitable patients from being 
referred due to their geographical location. There are 
NHS trusts/boards, most noticeably in rural Scotland 
and Northern Ireland where access to disease-modi-
fying IO services appears limited and linking up with 
neighbouring hospitals to set up formal referral path-
ways should be considered. What also remains unclear is 
what the current demand for IO services are generally, 
but particularly in these rural regions, as we have no 
data to suggest current arrangements are suboptimal. It 
would not be necessary or appropriate for all providers 
to liaise with IO services, and these should be facilitated 
through regional cancer networks with more integrated 
pathways of care.7 Currently there appears to be 136 out 
of 153 acute NHS trusts in England, which are listed to 
offer acute oncology services.8 Further work is required to 
elucidate whether there is any discrepancy in the regional 
demand and supply of disease-modifying IO.
The perceived barriers to starting up elective 
disease-modifying services stemmed from shortfalls in 
funding, staffing and support from other specialties. 
With tertiary centres undertaking much higher volumes 
of disease-modifying IO procedures, some smaller 
district general hospitals felt unsupported in starting up 
their own service, from financial considerations when 
purchasing the equipment to garnering support from 
allied specialties such as surgery and oncology. This is 
an important point as it highlights the need for greater 
awareness of the role of the interventional radiologist in 
oncology care and we must strive to work even closer with 
oncologists given the new evidence suggesting the added 
value of combination therapies and incorporation of IO 
procedures into European cancer guidelines.9 However, 
with the current model of centralising cancer services, 
these barriers would only be an issue if cancer centres 
were unable to provide IO. To improve patient selection 
for complex IO procedures, interventional radiologists 
should have a regular role in multidisciplinary team meet-
ings. With only 19 institutions (11%) currently having a 
formal IO lead clinician, there is a role for dispersed lead-
ership to achieve structural change in established cancer 
networks.
Local expertise and facilities help determine the IO that 
is offered. An example is the provision of disease-modi-
fying IO for the liver, which is centred around the national 
liver transplant units.10 Clearly image-guided tumour 
ablation, TACE and SIRT are effective therapies than 
can be used solely or in combination with chemotherapy 
or surgery to improve the outcome of such patients.11 12 
Participation in MDT discussions will also allow interven-
tional radiologists and radiologists familiar with IO tech-
niques to educate other clinicians on the role of IO in the 
management of patients and contribute towards improve-
ment and restructuring of services. This will also open 
opportunities to undertake collaborative research that 
will be higher impact and wider reaching to the oncology 
community.
The recurrent issue of lack of staffing within IR remains 
a barrier. Despite the promising provision of supportive 
IO, most departments are struggling to cope with the 
demand for basic vascular, urological and biliary proce-
dures, necessary to provide a sustainable out of hours 
service, without compounding this with additional work-
load and need for additional training for disease-modi-
fying IO.
Changes to the delivery of healthcare throughout the 
UK demands that IO treatments can demonstrate not 
only a therapeutic benefit but also cost-effectiveness. For 
units with a referral pathway for disease-modifying IO, 
there was a common theme that this set-up was more 
cost-effective than starting a service from scratch. Without 
knowledge of the actual demand for these IO procedures, 
there is no answer to this currently, and clinical investi-
gators must incorporate measures of cost-effectiveness 
and patient-reported outcomes into large-scale studies to 
provide more robust evidence.13 Even if these IO treat-
ments can be shown to be equally effective compared 
with the current standard of care but with significantly 
less morbidity, then it will allow the specialty to develop 
further; however, current studies have not offered defini-
tive conclusions.14 Building on the knowledge of these IO 
networks will allow better registry data that can be used 
to derive larger cohorts for future trials and also commis-
sioning of new services.
The limitations of the present study include those 
inherent in the survey/questionnaire format such as the 
subjective element depending on whether a superinten-
dent radiographer or consultant radiologist responded 
given their underlying experience and knowledge of their 
radiology services which could impact on the detail of 
their survey answers. The strengths of the survey include 
100% response rate from 179 acute NHS trusts/health 
boards which allowed a comprehensive map of both 
supportive and disease-modifying IO procedures offered 
in the UK that will help direct radiology/IO training, 
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future planning of new IO services and allow for more 
integrated cancer pathways.
cOnclusIOn
The provision of IO services in the UK is promising; 
however, collaboration and networking is necessary 
to ensure disease-modifying IO procedures are made 
accessible to all patients throughout the UK and to facil-
itate improved registry data collection for research and 
commissioning or funding of new services.
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